New drug trial offers hope for rare brain disease

NCT ID NCT05757141

First seen Nov 01, 2025 · Last updated May 06, 2026 · Updated 31 times

Summary

This study tests an experimental drug called fosigotifator in people with Vanishing White Matter disease, a rare genetic brain disorder. About 50 adults, children, and infants will receive the drug to see if it is safe and how the body processes it. The study lasts about 4 years and involves regular check-ups, blood tests, and questionnaires.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for VANISHING WHITE MATTER DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Amsterdam UMC, locatie VUmc /ID# 270955

    RECRUITING

    Amsterdam, North Holland, 1081 HV, Netherlands

  • Children's Hospital of Philadelphia

    RECRUITING

    Philadelphia, Pennsylvania, 19104, United States

  • Massachusetts General Hospital /ID# 270960

    RECRUITING

    Boston, Massachusetts, 02114, United States

  • McGill University Health Centre - Glen Site

    RECRUITING

    Montreal, Quebec, H3H2L9, Canada

  • University of Utah /ID# 255624

    RECRUITING

    Salt Lake City, Utah, 84112-5339, United States

Conditions

Explore the condition pages connected to this study.